Found: 244
Select item for more details and to access through your institution.
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 7, p. 859, doi. 10.1111/head.14775
- By:
- Publication type:
- Article
Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 4, p. 333, doi. 10.1111/head.14692
- By:
- Publication type:
- Article
Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 2, p. 339, doi. 10.1007/s40120-023-00575-5
- By:
- Publication type:
- Article
Commentary on 2022 guidelines on clinical trial design in cluster headache and further suggestions.
- Published in:
- Journal of Headache & Pain, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s10194-024-01732-3
- By:
- Publication type:
- Article
Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
- Published in:
- Journal of Headache & Pain, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s10194-023-01688-w
- By:
- Publication type:
- Article
Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience.
- Published in:
- Frontiers in Neurology, 2023, p. 1, doi. 10.3389/fneur.2023.1291102
- By:
- Publication type:
- Article
Sustained response of galcanezumab in migraine prevention: Patient‐level data from a post hoc analysis in patients with episodic or chronic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 10, p. 1380, doi. 10.1111/head.14494
- By:
- Publication type:
- Article
Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non‐interventional study using claims data from the United States.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 10, p. 1423, doi. 10.1111/head.14612
- By:
- Publication type:
- Article
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 5, p. 1533, doi. 10.1007/s40120-023-00529-x
- By:
- Publication type:
- Article
A Brief Review of Gepants.
- Published in:
- Current Pain & Headache Reports, 2023, v. 27, n. 9, p. 479, doi. 10.1007/s11916-023-01142-1
- By:
- Publication type:
- Article
Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 6, p. 730, doi. 10.1111/head.14536
- By:
- Publication type:
- Article
The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression.
- Published in:
- Journal of Headache & Pain, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s10194-023-01587-0
- By:
- Publication type:
- Article
Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 3, p. 377, doi. 10.1111/head.14469
- By:
- Publication type:
- Article
Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 1, p. 79, doi. 10.1111/head.14439
- By:
- Publication type:
- Article
Novel Migraine Treatments: A Review.
- Published in:
- Journal of Oral & Facial Pain & Headache, 2023, v. 37, n. 1, p. 27, doi. 10.11607/ofph.3163
- By:
- Publication type:
- Article
Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache.
- Published in:
- Cephalalgia, 2022, v. 42, n. 14, p. 1450, doi. 10.1177/03331024221120266
- By:
- Publication type:
- Article
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01519-4
- By:
- Publication type:
- Article
Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 8, p. 989, doi. 10.1111/head.14350
- By:
- Publication type:
- Article
External Concurrent Occipital and Trigeminal Neurostimulation Relieves Migraine Headache: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial.
- Published in:
- Pain & Therapy, 2022, v. 11, n. 3, p. 907, doi. 10.1007/s40122-022-00394-w
- By:
- Publication type:
- Article
Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 5, p. 624, doi. 10.1111/head.14313
- By:
- Publication type:
- Article
Erenumab dosage for migraine prevention: An evidence‐based narrative review with recommendations.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 4, p. 420, doi. 10.1111/head.14266
- By:
- Publication type:
- Article
Network meta‐analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 4, p. 482, doi. 10.1111/head.14283
- By:
- Publication type:
- Article
Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM).
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-09071-6
- By:
- Publication type:
- Article
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 263, doi. 10.1007/s40261-021-01115-5
- By:
- Publication type:
- Article
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 3, p. 329, doi. 10.1111/head.14284
- By:
- Publication type:
- Article
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
- Published in:
- JAMA Neurology, 2022, v. 79, n. 2, p. 159, doi. 10.1001/jamaneurol.2021.4678
- By:
- Publication type:
- Article
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 9, p. 1411, doi. 10.1111/head.14208
- By:
- Publication type:
- Article
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 9, p. 1421, doi. 10.1111/head.14206
- By:
- Publication type:
- Article
Timing and durability of response to erenumab in patients with chronic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 8, p. 1255, doi. 10.1111/head.14193
- By:
- Publication type:
- Article
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01303-w
- By:
- Publication type:
- Article
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura.
- Published in:
- Journal of Pain Research, 2021, v. 14, p. 2529, doi. 10.2147/JPR.S322292
- By:
- Publication type:
- Article
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01292-w
- By:
- Publication type:
- Article
A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 6, p. 838, doi. 10.1111/head.14135
- By:
- Publication type:
- Article
Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01238-2
- By:
- Publication type:
- Article
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 3, p. 438, doi. 10.1111/head.14053
- By:
- Publication type:
- Article
Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial.
- Published in:
- Journal of Pain Research, 2021, v. 14, p. 549, doi. 10.2147/JPR.S287571
- By:
- Publication type:
- Article
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
- Published in:
- Cephalalgia, 2021, v. 41, n. 1, p. 6, doi. 10.1177/0333102420973994
- By:
- Publication type:
- Article
Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study.
- Published in:
- Cephalalgia Reports, 2021, v. 4, p. 1, doi. 10.1177/25158163211040061
- By:
- Publication type:
- Article
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 1, p. 125, doi. 10.1111/head.14036
- By:
- Publication type:
- Article
Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability.
- Published in:
- International Journal of Environmental Research & Public Health, 2021, v. 18, n. 1, p. 246, doi. 10.3390/ijerph18010246
- By:
- Publication type:
- Article
No "Wearing‐Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 10, p. 2431, doi. 10.1111/head.13994
- By:
- Publication type:
- Article
Headache Currents Thanks You.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 10, p. 2653, doi. 10.1111/head.13984
- By:
- Publication type:
- Article
Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 8, p. 1601, doi. 10.1111/head.13897
- By:
- Publication type:
- Article
Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 8, p. 1793, doi. 10.1111/head.13899
- By:
- Publication type:
- Article
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 2, p. 337, doi. 10.1111/head.13688
- By:
- Publication type:
- Article
Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 1, p. 58, doi. 10.1111/head.13663
- By:
- Publication type:
- Article
The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 1, p. 178, doi. 10.1111/head.13716
- By:
- Publication type:
- Article
Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 1, p. 229, doi. 10.1111/head.13669
- By:
- Publication type:
- Article